

DAFTAR PUSTAKA

Abdelsayed, G.A. *et al.* (2015) ‘Tumors of the Anterior Prostate: Implications for Diagnosis and Treatment’, *Urology*, 85(6), pp. 1224–1228. Available at: <https://doi.org/10.1016/j.urology.2014.12.035>.

Abi Sen, A.A. *et al.* (2020) ‘A Classification Algorithm for Date Fruits’, *2020 7th International Conference on Computing for Sustainable Global Development (INDIACom)*, pp. 235–239. Available at: <https://doi.org/10.23919/INDIACom49435.2020.9083706>.

Abubakar, A.R. and Haque, M. (2020) ‘Preparation of Medicinal Plants: Basic Extraction and Fractionation Procedures for Experimental Purposes’, *Journal of Pharmacy & Bioallied Sciences*, 12(1), pp. 1–10. Available at: https://doi.org/10.4103/jpbs.JPBS_175_19.

Acevedo, S., Segovia, M.F. and Fuente-Ortega, E. de la (2024) ‘Emerging Perspectives in Zinc Transporter Research in Prostate Cancer: An Updated Review’, *Nutrients*, 16. Available at: <https://doi.org/10.3390/nu16132026>.

Ahmed, A., Bano, N. and Tayyab, M. (2016) ‘Phytochemical and therapeutic evaluation of date (*Phoenix dactylifera*). A review’, *J Pharm Altern Med*, 9, pp. 11–17.

Ahmed, S. *et al.* (2022) ‘Therapeutic potential of marine peptides in prostate cancer: Mechanistic insights’, *Marine drugs*, 20(8), p. 466.

Alghandour, R. *et al.* (2021) ‘Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED)’, *Urologic Oncology: Seminars and Original Investigations*, 39(12), p. 831.e1-831.e10. Available at: <https://doi.org/10.1016/j.urolonc.2021.05.020>.

Almaaty, A.H.A. *et al.* (2022) ‘Medicinal usage of some Arecaceae family members with potential anticancer effect’, *Journal of Biotech Research*, 13, pp. 55–63.

AlMalki, F.A. (2021) ‘Cytotoxic Activities of Phytochemical Components from Ethanol Extract of Ajwa Date on Human Hepatoma Cancer Cells in Vitro’, *Pharmacognosy Journal*, 13(6s), pp. 1664–1672. Available at: <https://doi.org/10.5530/pj.2021.13.214>.

Alqarni, M.M.M. *et al.* (2019) ‘Antioxidant and antihyperlipidemic effects of Ajwa date (*Phoenix dactylifera* L.) extracts in rats fed a cholesterol-rich diet’, *Journal of Food Biochemistry*, 43(8), p. e12933. Available at: <https://doi.org/10.1111/jfbc.12933>.

Andrysik, Z. and Espinosa, J.M. (2025) ‘Harnessing p53 for targeted cancer therapy: new advances and future directions’, *Transcription*, 16(1), pp. 3–46. Available at: <https://doi.org/10.1080/21541264.2025.2452711>.

Annala, M. *et al.* (2018) ‘Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.’, *Cancer discovery*, 8 4, pp. 444–457. Available at: <https://doi.org/10.1158/2159-8290.CD-17-0937>.

Antonarakis, E.S. *et al.* (2020) ‘Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study’, *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 38(5), pp. 395–405. Available at: <https://doi.org/10.1200/JCO.19.01638>.

Anwar, S. *et al.* (2022) ‘Role of Ajwa Date Fruit Pulp and Seed in the Management of Diseases through In Vitro and In Silico Analysis’, *Biology*, 11(1), p. 78. Available at: <https://doi.org/10.3390/biology11010078>.

Arigbede, O., Gbogbo, D. and Buxbaum, S.G. (2024) ‘Mutational burden among patients with metastatic prostate cancer differs by race in 3 key genes: An analysis of genomic and clinical data from the AACR Project GENIE biopharma collaborative in cBioPortal.’, *Journal of Clinical Oncology* [Preprint]. Available at: https://doi.org/10.1200/jco.2024.42.16_suppl.5106.

Bader, D.A. *et al.* (2018) ‘Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer’, *Nature Metabolism*, 1(1), pp. 70–85. Available at: <https://doi.org/10.1038/s42255-018-0002-y>.

Bai, B. *et al.* (2021) ‘Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents’, *Frontiers in Pharmacology*, 12. Available at: <https://doi.org/10.3389/fphar.2021.738235>.

Baliga, M.S. *et al.* (2011) ‘A review of the chemistry and pharmacology of the date fruits (*Phoenix dactylifera*)’, *Food Research International*, 44(7), pp. 1812–1822. Available at: <https://doi.org/10.1016/j.foodres.2010.07.004>.

Barata, P. *et al.* (2018) ‘A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)’, *Investigational New Drugs*, 36(3), pp. 451–457. Available at: <https://doi.org/10.1007/s10637-018-0574-0>.

Barsouk, Adam *et al.* (2020) ‘Epidemiology, staging and management of prostate cancer’, *Medical Sciences*, 8(3), p. 28.

Bellail, A.C. *et al.* (2010) ‘DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas’, *Journal of Cellular and Molecular Medicine*, 14(6a), pp. 1303–1317. Available at: <https://doi.org/10.1111/j.1582-4934.2009.00777.x>.

Bhat, F.A. *et al.* (2014) ‘Quercetin reverses EGF-induced epithelial to mesenchymal transition and invasiveness in prostate cancer (PC-3) cell line via EGFR/PI3K/Akt pathway’, *The Journal of Nutritional Biochemistry*, 25(11), pp. 1132–1139. Available at: <https://doi.org/10.1016/j.jnutbio.2014.06.008>.

Bilancio, A. *et al.* (2017) ‘Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation’, *Oncotarget*, 8, pp. 115620–115631. Available at: <https://doi.org/10.18632/oncotarget.23360>.

Bolis, M. *et al.* (2021) ‘Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression’, *Nature Communications*, 12. Available at: <https://doi.org/10.1038/s41467-021-26840-5>.

Bono, J.D. de *et al.* (2018) ‘Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss’, *Clinical Cancer Research*, 25, pp. 928–936. Available at: <https://doi.org/10.1158/1078-0432.CCR-18-0981>.

de Bono, J.S. *et al.* (2020) ‘Prostate carcinogenesis: inflammatory storms’, *Nature Reviews Cancer*, 20(8), pp. 455–469.

Bouhlali, E.D.T. *et al.* (2018) ‘Anti-inflammatory properties and phenolic profile of six Moroccan date fruit (*Phoenix dactylifera* L.) varieties’, *Journal of King Saud University - Science*, 30(4), pp. 519–526. Available at: <https://doi.org/10.1016/j.jksus.2017.08.011>.

Bray, F. *et al.* (2024) ‘Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries’, *CA: A Cancer Journal for Clinicians*, 74(3), pp. 229–263. Available at: <https://doi.org/10.3322/caac.21834>.

Brookman-May, S. *et al.* (2019) ‘Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).’, *European urology focus* [Preprint]. Available at: <https://doi.org/10.1016/j.euf.2018.02.007>.

Campbell, K.J. *et al.* (2018) ‘MCL-1 is a prognostic indicator and drug target in breast cancer’, *Cell Death & Disease*, 9(2), p. 19. Available at: <https://doi.org/10.1038/s41419-017-0035-2>.

Canesin, G. *et al.* (2020) ‘Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities’, *Current Opinion in Endocrine and Metabolic Research*, 10, pp. 36–42. Available at: <https://doi.org/10.1016/j.coemr.2020.02.004>.

Carceles-Cordon, M. *et al.* (2020) ‘Cellular rewiring in lethal prostate cancer: the architect of drug resistance’, *Nature Reviews Urology*, 17(5), pp. 292–307. Available at: <https://doi.org/10.1038/s41585-020-0298-8>.

Cavalcante, G.C. *et al.* (2019) ‘A Cell’s Fate: An Overview of the Molecular Biology and Genetics of Apoptosis’, *International Journal of Molecular Sciences*, 20(17), p. 4133. Available at: <https://doi.org/10.3390/ijms20174133>.

Chen, C. *et al.* (2018) ‘HIF-1 α induces immune escape of prostate cancer by regulating NCR1/NKp46 signaling through miR-224’, *Biochemical and Biophysical Research Communications*, 503(1), pp. 228–234. Available at: <https://doi.org/10.1016/j.bbrc.2018.06.007>.

Chen, T., Xu, J. and Fu, W. (2020) 'EGFR/FOXO3A/LXR- α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR- α /EGFR Shows Synthetic Lethality', *Frontiers in Oncology*, 10, p. 1688. Available at: <https://doi.org/10.3389/fonc.2020.01688>.

Cherrak, S.A. *et al.* (2016) 'In Vitro Antioxidant versus Metal Ion Chelating Properties of Flavonoids: A Structure-Activity Investigation', *PLOS ONE*. Edited by J. Chamani, 11(10), p. e0165575. Available at: <https://doi.org/10.1371/journal.pone.0165575>.

Conti, D.V. *et al.* (2021) 'Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction', *Nature Genetics*, 53(1), pp. 65–75. Available at: <https://doi.org/10.1038/s41588-020-00748-0>.

Cornford, P. *et al.* (2021) 'EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer', *European Urology*, 79(2), pp. 263–282. Available at: <https://doi.org/10.1016/j.eururo.2020.09.046>.

Corti, M. *et al.* (2022) 'Endocrine Disruptors and Prostate Cancer', *International Journal of Molecular Sciences*, 23. Available at: <https://doi.org/10.3390/ijms23031216>.

Dawson, N.A. *et al.* (2020) 'An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer', *Molecular Cancer Therapeutics*, 19(6), pp. 1373–1382. Available at: <https://doi.org/10.1158/1535-7163.MCT-19-0531>.

Descotes, J. (2019) 'Diagnosis of prostate cancer', *Asian Journal of Urology*, 6, pp. 129–136. Available at: <https://doi.org/10.1016/j.ajur.2018.11.007>.

Dess, R.T. *et al.* (2019) 'Association of black race with prostate cancer-specific and other-cause mortality', *JAMA oncology*, 5(7), pp. 975–983.

Dhiman, G. *et al.* (2019) 'Metadherin: A Therapeutic Target in Multiple Cancers', *Frontiers in Oncology*, 9, p. 349. Available at: <https://doi.org/10.3389/fonc.2019.00349>.

Dickerman, B. and Mucci, L. (2019) 'Metabolic Factors and Prostate Cancer Risk.', *Clinical chemistry*, 65 1, pp. 42–44. Available at: <https://doi.org/10.1373/clinchem.2018.287243>.

Ehsani, M., David, F.O. and Baniahmad, A. (2021) 'Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer', *Cancers*, 13(7), p. 1534.

Eid, N. *et al.* (2014) 'The impact of date palm fruits and their component polyphenols, on gut microbial ecology, bacterial metabolites and colon cancer cell proliferation', *Journal of Nutritional Science*, 3, p. e46. Available at: <https://doi.org/10.1017/jns.2014.16>.

El Sayed, S.M. (2022) 'Oxidative Stress in Hepatocarcinogenesis and Role of Antioxidant Therapy', in *Handbook of Oxidative Stress in Cancer: Mechanistic Aspects*. Springer, pp. 821–838.

Elmore, S. (2007) 'Apoptosis: A Review of Programmed Cell Death', *Toxicologic Pathology* [Preprint]. Available at: <https://doi.org/10.1080/01926230701320337>.

Elrod, H.A. and Sun, S.-Y. (2008) ‘Modulation of death receptors by cancer therapeutic agents’, *Cancer Biology & Therapy*, 7(2), pp. 163–173. Available at: <https://doi.org/10.4161/cbt.7.2.5335>.

Ene, C.-V. *et al.* (2022) ‘IL-6 Signaling Link between Inflammatory Tumor Microenvironment and Prostatic Tumorigenesis’, *Analytical Cellular Pathology*. Edited by Y.P. Lim, 2022, pp. 1–10. Available at: <https://doi.org/10.1155/2022/5980387>.

Erdogan, S. *et al.* (2017) ‘The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy’, *Biomedicine & Pharmacotherapy*, 88, pp. 210–217.

Feng, L.-X. *et al.* (2014) ‘Synergistic Enhancement of Cancer Therapy Using a Combination of Ceramide and Docetaxel’, *International Journal of Molecular Sciences*, 15(3), pp. 4201–4220. Available at: <https://doi.org/10.3390/ijms15034201>.

Feng, Q. and He, B. (2019) ‘Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer’, *Frontiers in Oncology*, 9, p. 858. Available at: <https://doi.org/10.3389/fonc.2019.00858>.

Firdous, A. *et al.* (2014) ‘Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway’, *Food & Function*, 5(10), pp. 2632–2645.

Fizazi, K. *et al.* (2019) ‘Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.’, *The Lancet. Oncology*, 20 5, pp. 686–700. Available at: [https://doi.org/10.1016/S1470-2045\(19\)30082-8](https://doi.org/10.1016/S1470-2045(19)30082-8).

Fletcher, S.A. *et al.* (2020) ‘Geographic distribution of racial differences in prostate cancer mortality’, *JAMA network open*, 3(3), pp. e201839–e201839.

Formaggio, N., Rubin, M.A. and Theurillat, J.-P. (2021) ‘Loss and revival of androgen receptor signaling in advanced prostate cancer’, *Oncogene*, 40(7), pp. 1205–1216. Available at: <https://doi.org/10.1038/s41388-020-01598-0>.

Franko, A. *et al.* (2020) ‘Human Prostate Cancer Is Characterized by an Increase in Urea Cycle Metabolites’, *Cancers*, 12. Available at: <https://doi.org/10.3390/cancers12071814>.

Fujita, K. and Nonomura, N. (2019) ‘Role of Androgen Receptor in Prostate Cancer: A Review’, *The World Journal of Men’s Health*, 37(3), p. 288. Available at: <https://doi.org/10.5534/wjmh.180040>.

Ganai, S.A. (2017) ‘Plant-derived flavone Apigenin: The small-molecule with promising activity against therapeutically resistant prostate cancer’, *Biomedicine & Pharmacotherapy*, 85, pp. 47–56. Available at: <https://doi.org/10.1016/j.biopha.2016.11.130>.

Ganai, S.A. *et al.* (2021) ‘Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated’, *Phytotherapy Research*, 35(7), pp. 3509–3532. Available at: <https://doi.org/10.1002/ptr.7044>.

Gandaglia, G. *et al.* (2021) ‘Epidemiology and prevention of prostate cancer’, *European urology oncology*, 4(6), pp. 877–892.

Gilany, K. *et al.* (2015) ‘Exploring the human seminal plasma proteome: an unexplored gold mine of biomarker for male infertility and male reproduction disorder’, *Journal of Reproduction & Infertility*, 16(2), pp. 61–71.

Giona, S. (2021) ‘The epidemiology of prostate cancer’, *Exon Publications*, pp. 1–15.

Godugu, K. *et al.* (2020) ‘Nanoformulated Ajwa (Phoenix Dactylifera) bioactive compounds improve the safety of doxorubicin without compromising its anticancer efficacy in breast cancer’, *Molecules*, 25(11), p. 2597.

Gong, Y. *et al.* (2007) ‘Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas’, *PLOS Medicine*, 4(10), p. e294. Available at: <https://doi.org/10.1371/journal.pmed.0040294>.

Gortat, A. *et al.* (2015) ‘Apaf1 inhibition promotes cell recovery from apoptosis’, *Protein & Cell*, 6(11), pp. 833–843. Available at: <https://doi.org/10.1007/s13238-015-0200-2>.

Grossebrummel, H. *et al.* (2016) ‘Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways’, *International Journal of Oncology*, 48(2), pp. 793–800. Available at: <https://doi.org/10.3892/ijo.2015.3274>.

Hamdy, F. *et al.* (2023) ‘Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.’, *The New England journal of medicine* [Preprint]. Available at: <https://doi.org/10.1056/nejmoa2214122>.

Hamed, M.M., Mohamed, M. and Ahmed, W.S. (2017) ‘Antioxidant potential, antitumor activity and phenolic profile of Phoenix dactylifera Linn’, *Int J Pharm Pharm Sci*, 9(5), pp. 130–136.

Hasanah, A. M. *et al.* (2023) ‘Perbandingan Kadar Total Flavonoid Metode Infusa dan Rendaman Buah Kurma Ajwa (Phoenix dactylifera L.) Menggunakan Spektrofotometri UV-Vis. Jurnal Ilmiah Global Farmasi, 1(1), 09–17. <https://doi.org/10.21111/jigf.v1i1.2>’.

He, Y. *et al.* (2019) ‘Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells’, *Oncogene*, 38(13), pp. 2337–2350. Available at: <https://doi.org/10.1038/s41388-018-0583-7>.

Hidayatulla, F. *et al.* (2024) ‘Effects of metformin and silodosin as supplementary treatments to abiraterone on human telomerase reverse transcriptase (hTERT) level in metastatic castration-resistant prostate cancer (mCRPC) cells: An in vitro study’, *Narra J*, 4(1), pp. e680–e680. Available at: <https://doi.org/10.52225/narra.v4i1.680>.

Ho, C.-J. *et al.* (2019) ‘Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress’, *Cell Death Discovery*, 5. Available at: <https://doi.org/10.1038/s41420-019-0211-5>.

Hogh-Binder, S.A. *et al.* (2023) ‘Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy’, *Cancers*, 15(9), p. 2496. Available at: <https://doi.org/10.3390/cancers15092496>.

Hosseinzadeh, E. *et al.* (2020) ‘Flavonoid-based cancer therapy: an updated review’, *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, 20(12), pp. 1398–1414.

Hoyle, A. *et al.* (2019) ‘Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer.’, *European urology* [Preprint]. Available at: <https://doi.org/10.1016/j.eururo.2019.08.006>.

Hsieh, Y.-H. *et al.* (2022) ‘Targeting of Mcl-1 Expression by MiRNA-3614-5p Promotes Cell Apoptosis of Human Prostate Cancer Cells’, *International Journal of Molecular Sciences*, 23(8), p. 4194. Available at: <https://doi.org/10.3390/ijms23084194>.

Hu, K. *et al.* (2018) ‘Metadherin is an apoptotic modulator in prostate cancer through miR-342-3p regulation’, *Saudi Journal of Biological Sciences*, 25(5), pp. 975–981. Available at: <https://doi.org/10.1016/j.sjbs.2018.04.015>.

Huang, Y. *et al.* (2019) ‘Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA’, *Cell Cycle*, 18, pp. 3442–3455. Available at: <https://doi.org/10.1080/15384101.2019.1688951>.

Imran, M. *et al.* (2019) ‘Luteolin, a flavonoid, as an anticancer agent: A review’, *Biomedicine & Pharmacotherapy*, 112, p. 108612.

Ittmann, M. (2018) ‘Anatomy and Histology of the Human and Murine Prostate’, *Cold Spring Harbor Perspectives in Medicine*, 8(5), p. a030346. Available at: <https://doi.org/10.1101/cshperspect.a030346>.

Izzo, S., Naponelli, V. and Bettuzzi, S. (2020) ‘Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention’, *Nutrients*, 12(4), p. 1010. Available at: <https://doi.org/10.3390/nu12041010>.

Jandou, I. (2021) ‘The epidemiological determinants of prostate cancer: a retrospective analytical study’, *Urology & Nephrology Open Access Journal* [Preprint]. Available at: <https://doi.org/10.15406/UNOAJ.2021.09.00304>.

Jividen, K. *et al.* (2018) ‘Genomic analysis of DNA repair genes and androgen signaling in prostate cancer’, *BMC Cancer*, 18(1), p. 960. Available at: <https://doi.org/10.1186/s12885-018-4848-x>.

Kabiru, S.M. *et al.* (2016) ‘An Assessment of Knowledge Level of Date Palm (*Phoenix dactylifera* L) Farmers in Dutse Local Government Area of Jigawa State, Nigeria’, *World Journal of Agricultural Research*, 4(2), pp. 36–42. Available at: <https://doi.org/10.12691/wjar-4-2-1>.

Kalinska, M. *et al.* (2016) ‘Kallikreins - The melting pot of activity and function’, *Biochimie*, 122, pp. 270–282. Available at: <https://doi.org/10.1016/j.biochi.2015.09.023>.

Kazantseva, M. *et al.* (2019) ‘The $\Delta 133p53\beta$ isoform promotes an immunosuppressive environment leading to aggressive prostate cancer’, *Cell Death & Disease*, 10(9), p. 631. Available at: <https://doi.org/10.1038/s41419-019-1861-1>.

Kazmi, N. *et al.* (2019) ‘Appraising causal relationships of dietary, nutritional and physical-activity exposures with overall and aggressive prostate cancer: two-sample Mendelian-randomization study based on 79 148 prostate-cancer cases and 61 106 controls.’, *International journal of epidemiology* [Preprint]. Available at: <https://doi.org/10.1093/ije/dyz235>.

Kehr, S. *et al.* (2020) ‘Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis.’, *Cancer letters* [Preprint]. Available at: <https://doi.org/10.1016/j.canlet.2020.02.041>.

Kerr, J.F., Wyllie, A.H. and Currie, A.R. (1972) ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’, *British Journal of Cancer*, 26(4), pp. 239–257. Available at: <https://doi.org/10.1038/bjc.1972.33>.

Khalid, S. *et al.* (2017) ‘A review on chemistry and pharmacology of Ajwa date fruit and pit’. Available at: <https://repository.adu.ac.ae/handle/1/6656> (Accessed: 24 January 2025).

Khan, F. *et al.* (2016) ‘Ajwa Date (*Phoenix dactylifera* L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest’, *PLoS ONE*, 11(7), p. e0158963. Available at: <https://doi.org/10.1371/journal.pone.0158963>.

Khan, M. *et al.* (2021) ‘Phytochemicals from Ajwa dates pulp extract induce apoptosis in human triple-negative breast cancer by inhibiting AKT/mTOR pathway and modulating Bcl-2 family proteins’, *Scientific Reports*, 11. Available at: <https://doi.org/10.1038/s41598-021-89420-z>.

Khan, S. *et al.* (2017) ‘The influence of menopause on urinary incontinence in the women of the community: a cross-sectional study from North India’, *Int J Reprod Contracept Obstetr Gynecol*, 6(3), pp. 911–8.

Kim, J.A. *et al.* (2015) ‘Fisetin, a dietary flavonoid, induces apoptosis of cancer cells by inhibiting HSF1 activity through blocking its binding to the hsp70 promoter’, *Carcinogenesis*, 36(6), pp. 696–706. Available at: <https://doi.org/10.1093/carcin/bgv045>.

Kim, J.S. *et al.* (2023) ‘Identification of Genes Involved in EGF-Induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers’, *Cancer Research and Treatment : Official Journal of Korean Cancer Association*, 55, pp. 737–756. Available at: <https://doi.org/10.4143/crt.2022.1414>.

Koirala, M. and DiPaola, M. (2024) ‘Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment’, *Biomedicines*, 12(8), p. 1801. Available at: <https://doi.org/10.3390/biomedicines12081801>.

Koushyar, S. *et al.* (2022) ‘Exploring the Wnt pathway as a therapeutic target for prostate cancer’, *Biomolecules*, 12(2), p. 309.

- Kumar, P. *et al.* (2021) 'Potential of Flavonoids as Anticancer Drugs', *Phytopharmaceuticals: Potential Therapeutic Applications*, pp. 135–159.
- Lahlou, A. *et al.* (2022) 'Arecaceae fruits: Fatty acids, phenolic compounds and in vitro antitumor activity', *Food Bioscience*, 50, p. 102181.
- Lall, J. and Nagar, O. (2017) 'Comparative study of post placental cut insertion following vaginal and caesarean delivery', *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, 6(3), p. 901. Available at: <https://doi.org/10.18203/2320-1770.ijrcog20170553>.
- Lall, R.K., Adhami, V.M. and Mukhtar, H. (2016) 'Dietary flavonoid fisetin for cancer prevention and treatment', *Molecular nutrition & food research*, 60(6), pp. 1396–1405.
- Lewis (1982) 'Industrial and business forecasting methods. London: Butterworth Scientific'.
- Li, J. *et al.* (2020) 'p53/PGC-1 α -mediated mitochondrial dysfunction promotes PC3 prostate cancer cell apoptosis', *Molecular Medicine Reports*, 22(1), pp. 155–164. Available at: <https://doi.org/10.3892/mmr.2020.11121>.
- Li, M.X. and Dewson, G. (2015) 'Mitochondria and apoptosis: emerging concepts', *F1000prime Reports*, 7, p. 42. Available at: <https://doi.org/10.12703/P7-42>.
- Li, X. *et al.* (2024) 'Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL-1', *Oncology Letters*, 27. Available at: <https://doi.org/10.3892/ol.2024.14217>.
- Liu, Y. *et al.* (2019) 'The androgen receptor regulates a druggable translational regulon in advanced prostate cancer', *Science Translational Medicine*, 11(503), p. eaaw4993. Available at: <https://doi.org/10.1126/scitranslmed.aaw4993>.
- Liu, Y.-H. *et al.* (2015) 'Quinolone-indolone conjugate induces apoptosis by inhibiting the EGFR-STAT3-HK2 pathway in human cancer cells', *Molecular Medicine Reports*, 12(2), pp. 2749–2756. Available at: <https://doi.org/10.3892/mmr.2015.3716>.
- Mahon, K.L. *et al.* (2018) 'P53 as a predictor of clinical outcome in localized prostate cancer.', *Journal of Clinical Oncology*, 36(6_suppl), pp. 57–57. Available at: https://doi.org/10.1200/JCO.2018.36.6_suppl.57.
- Markaverich, B. *et al.* (2010) 'Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells', *The Journal of Steroid Biochemistry and Molecular Biology*, 122, pp. 219–231. Available at: <https://doi.org/10.1016/j.jsbmb.2010.06.006>.
- Mathangasinghe, Y. *et al.* (2020) 'Morphology of ejaculatory ducts: A systematic review', *Clinical Anatomy*, 33, pp. 1164–1175. Available at: <https://doi.org/10.1002/ca.23557>.
- Mattiuzzi, C. and Lippi, G. (2019) 'Current Cancer Epidemiology', *Journal of Epidemiology and Global Health*, 9(4), p. 217. Available at: <https://doi.org/10.2991/jegh.k.191008.001>.

Mehraein-Ghomi, F. *et al.* (2015) ‘Inhibitor of p52 NF- κ B subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81)’, *Genes & Cancer*, 6(9–10), pp. 428–444. Available at: <https://doi.org/10.18632/genesandcancer.77>.

Messner, E. *et al.* (2020) ‘The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy’, *Biomedicines*, 8. Available at: <https://doi.org/10.3390/biomedicines8100422>.

Mills, I.G. (2014) ‘Maintaining and reprogramming genomic androgen receptor activity in prostate cancer’, *Nature Reviews Cancer*, 14(3), pp. 187–198. Available at: <https://doi.org/10.1038/nrc3678>.

Mirza, M.B. *et al.* (2018) ‘Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells’, *Journal of Ethnopharmacology*, 218, pp. 35–44. Available at: <https://doi.org/10.1016/j.jep.2018.02.030>.

Mitsogianni, M. *et al.* (2023) ‘An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer’, *Expert Opinion on Pharmacotherapy*, 24(16), pp. 1765–1774. Available at: <https://doi.org/10.1080/14656566.2023.2244415>.

Mitsuzuka, K. and Arai, Y. (2018) ‘Metabolic changes in patients with prostate cancer during androgen deprivation therapy’, *International Journal of Urology*, 25(1), pp. 45–53. Available at: <https://doi.org/10.1111/iju.13473>.

Mittal, P. *et al.* (2021) ‘A review on myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy.’, *International journal of biological macromolecules* [Preprint]. Available at: <https://doi.org/10.1016/j.ijbiomac.2021.07.166>.

Mohamed, F. *et al.* (2021) ‘Design, synthesis, and biological evaluation of novel EGFR inhibitors containing 5-chloro-3-hydroxymethyl-indole-2-carboxamide scaffold with apoptotic antiproliferative activity.’, *Bioorganic chemistry*, 112. Available at: <https://doi.org/10.1016/j.bioorg.2021.104960>.

Mohamed, S.A. *et al.* (2016) ‘Total phenolic and flavonoid contents and antioxidant activities of sixteen commercial date cultivars grown in Saudi Arabia’, *RSC Advances*, 6(50), pp. 44814–44819. Available at: <https://doi.org/10.1039/C6RA02831D>.

Mottet, N. *et al.* (2021) ‘EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent’, *European Urology*, 79(2), pp. 243–262. Available at: <https://doi.org/10.1016/j.eururo.2020.09.042>.

Mukhtar, E. *et al.* (2015) ‘Dietary flavonoid fisetin binds to β -tubulin and disrupts microtubule dynamics in prostate cancer cells’, *Cancer letters*, 367(2), pp. 173–183.

Mustafin, R.N. (2022) ‘Relationship of TP53 gene with retroelements in urogenital organs carcinogenesis’, *Cancer Urology*, 18(1), pp. 136–142. Available at: <https://doi.org/10.17650/1726-9776-2022-18-1-136-142>.

- Nabid, A. *et al.* (2018) ‘Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial’, *European Urology*, 74(4), pp. 432–441. Available at: <https://doi.org/10.1016/j.eururo.2018.06.018>.
- Nakano, T. *et al.* (2020) ‘Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer’, *Anticancer Research*, 40(2), pp. 1007–1014. Available at: <https://doi.org/10.21873/anticancer.14035>.
- Nastaly, P. *et al.* (2020) ‘EGFR as a stable marker of prostate cancer dissemination to bones’, *British Journal of Cancer*, 123(12), pp. 1767–1774. Available at: <https://doi.org/10.1038/s41416-020-01052-8>.
- Ni, F. *et al.* (2012) ‘Flavonoid Ampelopsin Inhibits the Growth and Metastasis of Prostate Cancer In Vitro and in Mice’, *PLoS ONE*. Edited by R.K. Srivastava, 7(6), p. e38802. Available at: <https://doi.org/10.1371/journal.pone.0038802>.
- O’Brien, M.A. and Kirby, R. (2008) ‘Apoptosis: A review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease’, *Journal of Veterinary Emergency and Critical Care*, 18(6), pp. 572–585. Available at: <https://doi.org/10.1111/j.1476-4431.2008.00363.x>.
- Pan, K. *et al.* (2021) ‘Direct interaction of β -catenin with nuclear ESM1 supports stemness of metastatic prostate cancer’, *The EMBO Journal*, 40(4), p. e105450. Available at: <https://doi.org/10.15252/embj.2020105450>.
- Pandey, P. *et al.* (2023) ‘Targeting Wnt/ β -Catenin Pathway by Flavonoids: Implication for Cancer Therapeutics’, *Nutrients*, 15(9), p. 2088.
- Pascal, L.E. *et al.* (2018) ‘EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer’, *Neoplasia*, 20(4), pp. 351–363. Available at: <https://doi.org/10.1016/j.neo.2018.01.011>.
- Patterson, J.C. *et al.* (2022) ‘Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.’, *Cancer research* [Preprint]. Available at: <https://doi.org/10.1158/0008-5472.CAN-22-1533>.
- Pernar, C.H. *et al.* (2018) ‘The epidemiology of prostate cancer’, *Cold Spring Harbor perspectives in medicine*, p. a030361.
- Pfeffer, C.M. and Singh, A.T.K. (2018) ‘Apoptosis: A Target for Anticancer Therapy’, *International Journal of Molecular Sciences*, 19(2), p. 448. Available at: <https://doi.org/10.3390/ijms19020448>.
- Pham, T.-H. *et al.* (2020) ‘STAT3 and p53: Dual Target for Cancer Therapy’, *Biomedicines*, 8(12), p. 637. Available at: <https://doi.org/10.3390/biomedicines8120637>.
- Pignot, G. *et al.* (2018) ‘Systemic treatments for high-risk localized prostate cancer’, *Nature reviews Urology*, 15(8), pp. 498–510.

Pisani, C. *et al.* (2020) ‘Apoptotic and predictive factors by Bax, Caspases 3/9, Bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose’, *Scientific Reports*, 10. Available at: <https://doi.org/10.1038/s41598-020-64062-9>.

Puig, P. *et al.* (2019) ‘Multiple immunofluorescence assay identifies upregulation of Active β -catenin in prostate cancer’, *BMC Research Notes*, 12(1), p. 68. Available at: <https://doi.org/10.1186/s13104-019-4100-z>.

Qian, K. *et al.* (2020) ‘A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype’, *Oncogene*, 39(44), pp. 6871–6878. Available at: <https://doi.org/10.1038/s41388-020-01476-9>.

Rah, B. *et al.* (2022) ‘JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies’, *Frontiers in Pharmacology*, 13, p. 821344. Available at: <https://doi.org/10.3389/fphar.2022.821344>.

Rajput, M. *et al.* (2021) ‘EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways’, *Life Sciences*, 286, p. 120031. Available at: <https://doi.org/10.1016/j.lfs.2021.120031>.

Rawla, P. (2019) ‘Epidemiology of prostate cancer’, *World journal of oncology*, 10(2), p. 63.

Rebello, R. *et al.* (2021) ‘Prostate cancer’, *Nature Reviews Disease Primers*, 7, pp. 1–27. Available at: <https://doi.org/10.1038/s41572-020-00243-0>.

Reiner, T. *et al.* (2015) ‘Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage’, *Oncoscience*, 2(8), pp. 703–715. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580064/> (Accessed: 10 March 2025).

Renehan, A.G., Booth, C. and Potten, C.S. (2001) ‘What is apoptosis, and why is it important?’, *BMJ: British Medical Journal*, 322(7301), pp. 1536–1538. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1120576/> (Accessed: 28 January 2025).

Rengarajan, T. (2016) ‘The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways’, *European Journal of Pharmacology* [Preprint].

Rezaei, S.M. *et al.* (2022) ‘Segmentation of the prostate, its zones, anterior fibromuscular stroma, and urethra on the MRIs and multimodality image fusion using U-Net model’, *Quantitative Imaging in Medicine and Surgery*, 12, pp. 4786–4804. Available at: <https://doi.org/10.21037/qims-22-115>.

Royani, I. *et al.* (2019) ‘Effect of Ajwa Dates Consumption to Inhibit the Progression of Preeclampsia Threats on Mean Arterial Pressure and Roll-Over Test’, *BioMed Research International*, 2019, p. 2917895. Available at: <https://doi.org/10.1155/2019/2917895>.

Rybak, J., Magiera, B. and Magiera, K. (2023) ‘Prostate cancer - risk factors and prevention strategies’, *Journal of Education, Health and Sport* [Preprint]. Available at: <https://doi.org/10.12775/jehs.2023.21.01.018>.

Safitri, M.D., Fibonacci, A. and Latifah, R.N. (2020) ‘Anti-tumor and anti-cancer activity test from Nabeez Ajwa Dates (*Phoenix dactylifera* L.) water’, *Journal of Natural Sciences and Mathematics Research*, 6(1), pp. 17–25.

Sahih al-Bukhari (no date) *Hadith No. 664*. (Book 7).

Sanches, B. *et al.* (2021) ‘Stromal cell interplay in prostate development, physiology, and pathological conditions’, *The Prostate*, 81, pp. 926–937. Available at: <https://doi.org/10.1002/pros.24196>.

Sanford, T. *et al.* (2020) ‘Quantitative Characterization of the Prostatic Urethra Using MRI: Implications for Lower Urinary Tract Symptoms in Patients with Benign Prostatic Hyperplasia.’, *Academic radiology* [Preprint]. Available at: <https://doi.org/10.1016/j.acra.2020.03.017>.

Sani, I.H. *et al.* (2015) ‘Phoenix dactylifera Linn as a potential novel anti-oxidant in treating major opioid toxicity’, *Journal of Applied Pharmaceutical Science*, 5,(8), pp. 167–172. Available at: <https://doi.org/10.7324/JAPS.2015.50826>.

Santer, F. *et al.* (2013) ‘Androgenic regulation of the anti-apoptotic Bcl-2 family member Mcl-1 in prostate cancer cells.’, *Cancer Research*, 73, pp. 1726–1726. Available at: <https://doi.org/10.1158/1538-7445.AM2013-1726>.

Satari, A. *et al.* (2021) ‘Rutin: a flavonoid as an effective sensitizer for anticancer therapy; insights into multifaceted mechanisms and applicability for combination therapy’, *Evidence-based complementary and alternative medicine*, 2021.

Sathianathen, N. *et al.* (2020) ‘Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.’, *The Cochrane database of systematic reviews*, 12. Available at: <https://doi.org/10.1002/14651858.CD013245.pub2>.

Schaeffer, E. *et al.* (2021) ‘NCCN Guidelines Insights: Prostate Cancer, Version 1.2021: Featured Updates to the NCCN Guidelines’, *Journal of the National Comprehensive Cancer Network*, 19(2), pp. 134–143. Available at: <https://doi.org/10.6004/jnccn.2021.0008>.

Shahbaz, K. *et al.* (2022) ‘Cytotoxic and Antioxidant Effects of Phoenix dactylifera L. (Ajwa Date Extract) on Oral Squamous Cell Carcinoma Cell Line’, *BioMed Research International*, 2022, p. 5792830. Available at: <https://doi.org/10.1155/2022/5792830>.

Shahdadi, F., Mirzaei, H.O. and Daraei Garmakhany, A. (2015) ‘Study of phenolic compound and antioxidant activity of date fruit as a function of ripening stages and drying process’, *Journal of Food Science and Technology*, 52(3), pp. 1814–1819. Available at: <https://doi.org/10.1007/s13197-013-1177-6>.

Shalaby, A. *et al.* (2024) ‘Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy’, *Asian Pacific Journal of Cancer Prevention : APJCP*, 25, pp. 2193–2201. Available at: <https://doi.org/10.31557/APJCP.2024.25.6.2193>.

Shankar, E. *et al.* (2019) ‘Complex Systems Biology Approach in Connecting PI3K-Akt and NF- κ B Pathways in Prostate Cancer’, *Cells*, 8(3), p. 201. Available at: <https://doi.org/10.3390/cells8030201>.

Sharmila, G. *et al.* (2014) ‘Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model’, *Clinical Nutrition*, 33(4), pp. 718–726. Available at: <https://doi.org/10.1016/j.clnu.2013.08.011>.

Shtivelman, E., Beer, T.M. and Evans, C.P. (2014) ‘Molecular pathways and targets in prostate cancer’, *Oncotarget*, 5(17), pp. 7217–7259. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202120/> (Accessed: 15 April 2025).

Siddiqui, S. *et al.* (2019) ‘Cytostatic and anti-tumor potential of Ajwa date pulp against human hepatocellular carcinoma HepG2 cells’, *Scientific reports*, 9(1), p. 245.

Simon, I. *et al.* (2021) ‘Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation’, *Cancers*, 13. Available at: <https://doi.org/10.3390/cancers13061483>.

Sowalsky, A.G. *et al.* (2018) ‘Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations’, *Cancer Research*, 78(16), pp. 4716–4730. Available at: <https://doi.org/10.1158/0008-5472.CAN-18-0610>.

Student, S. *et al.* (2020) ‘Anti-androgen hormonal therapy for cancer and other diseases’, *European Journal of Pharmacology*, 866, p. 172783. Available at: <https://doi.org/10.1016/j.ejphar.2019.172783>.

Taitt, H.E. (2018) ‘Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location’, *American journal of men’s health*, 12(6), pp. 1807–1823.

Takahara, K. *et al.* (2022) ‘Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate’, *International Journal of Urology: Official Journal of the Japanese Urological Association*, 29(3), pp. 229–234. Available at: <https://doi.org/10.1111/iju.14754>.

Tantawy, S.I. *et al.* (2023) ‘Targeting MCL-1 protein to treat cancer: opportunities and challenges’, *Frontiers in Oncology*, 13, p. 1226289. Available at: <https://doi.org/10.3389/fonc.2023.1226289>.

Testa, U., Castelli, G. and Pelosi, E. (2019) ‘Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications’, *Medicines*, 6. Available at: <https://doi.org/10.3390/medicines6030082>.

Tímár, J. (2019) ‘[Molecular pathology of prostate cancer].’, *Magyar onkologia*, 63 1, pp. 5–9.

- Tong, J. *et al.* (2018) 'Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins', *Cancer Research*, 78(16), pp. 4704–4715. Available at: <https://doi.org/10.1158/0008-5472.CAN-18-0399>.
- Uribe, M.L., Marrocco, I. and Yarden, Y. (2021) 'EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance', *Cancers*, 13(11), p. 2748. Available at: <https://doi.org/10.3390/cancers13112748>.
- Verze, P., Cai, T. and Lorenzetti, S. (2016) 'The role of the prostate in male fertility, health and disease', *Nature Reviews Urology*, 13(7), pp. 379–386. Available at: <https://doi.org/10.1038/nrurol.2016.89>.
- Wang, C. *et al.* (2024) 'TP53 Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications', *Cancers*, 16(17), p. 3069. Available at: <https://doi.org/10.3390/cancers16173069>.
- Wang, Fan *et al.* (2020) 'Wnt/ β -catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation', *Biochemical and Biophysical Research Communications*, 527(1), pp. 242–249. Available at: <https://doi.org/10.1016/j.bbrc.2020.04.112>.
- Wanjari, U.R. *et al.* (2023) 'Role of Metabolism and Metabolic Pathways in Prostate Cancer', *Metabolites*, 13. Available at: <https://doi.org/10.3390/metabo13020183>.
- Windi Riyadi (2018) 'Ekstraksi biji kurma (*Phoenix dactylifera* L.) dengan metode sokletasi dan karakterisasinya'.
- Wu, T. *et al.* (2023) 'Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy', *European Journal of Medicinal Chemistry*, 260, p. 115774.
- Wu, Z. *et al.* (2018) 'Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer', *Cancer Medicine*, 7(4), pp. 1546–1559. Available at: <https://doi.org/10.1002/cam4.1419>.
- Xiang, W., Yang, C.-Y. and Bai, L. (2018) 'MCL-1 inhibition in cancer treatment', *OncoTargets and therapy*, 11, pp. 7301–7314. Available at: <https://doi.org/10.2147/OTT.S146228>.
- Xing, Z. *et al.* (2020) 'The long non-coding RNA LINC00473 contributes to cell proliferation via JAK-STAT3 signaling pathway by regulating miR-195-5p/SEPT2 axis in prostate cancer', *Bioscience Reports*, 40(9), p. BSR20191850. Available at: <https://doi.org/10.1042/BSR20191850>.
- Xu, S. *et al.* (2023) 'Prostate zones and tumor morphological parameters on magnetic resonance imaging for predicting the tumor-stage diagnosis of prostate cancer', *Diagnostic and Interventional Radiology*, 29, pp. 753–760. Available at: <https://doi.org/10.4274/dir.2023.232284>.
- Xue, Y.-N. *et al.* (2019) 'Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation', *Cancer Medicine*, 8, pp. 2462–2473. Available at: <https://doi.org/10.1002/cam4.2130>.

Yang, J. *et al.* (2019) ‘Inhibition of Karyopherin beta 1 suppresses prostate cancer growth’, *Oncogene*, 38(24), pp. 4700–4714. Available at: <https://doi.org/10.1038/s41388-019-0745-2>.

Zhang, C. *et al.* (2014) ‘Antioxidant, antiinflammatory and antitumor activities of 29 varieties of date fruits’, *Planta Medica*, 80(10), p. PE11.

Zhang, Z. *et al.* (2020) ‘Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer’, *Cancer Cell*, 38(2), pp. 279-296.e9. Available at: <https://doi.org/10.1016/j.ccell.2020.06.005>.

Zhu, C. *et al.* (2018) ‘Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer’, *Journal of Cellular Physiology*, 233(2), pp. 1104–1119. Available at: <https://doi.org/10.1002/jcp.25968>.

Ziglioli, F. *et al.* (2023) ‘Impact of modifiable lifestyle risk factors for prostate cancer prevention: a review of the literature’, *Frontiers in Oncology*, 13. Available at: <https://doi.org/10.3389/fonc.2023.1203791>.

Zulfahmidah, Z., Sri Wahyuni, M, R. and F.Bustan, A. (2021) ‘Efektifitas Kurma Ajwa dalam berbagai Penyakit’, *Indonesian Journal of Health*, 2(01), pp. 18–30. Available at: <https://doi.org/10.33368/inajoh.v2i1.22>.